Should direct-to-consumer personalized peptide and GLP-1 therapies for lifestyle optimization be restricted?

With the rise of platforms offering personalized peptides and GLP-1 receptor agonists directly to consumers (such as RonanRX), the boundary between medical treatment and lifestyle biohacking is blurring. Proponents argue that direct access to personalized biotechnology empowers individuals to optimize their health, longevity, and metabolic wellness. Critics, however, warn that bypassing traditional clinical oversight for cosmetic weight loss and anti-aging poses severe long-term health risks and exacerbates healthcare inequality.